SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up ...

SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up t ...

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress ...

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7 ...

For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41512 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) | Nevada | 27-3046338 | | --- | --- ...

— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatme ...

SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.  The patent, titled “Composi ...

The SS25 collection will be available globally on April 17NEW YORK, April 17, 2025 /PRNewswire/ -- Saucony, a global performance running and lifestyle brand, today revealed the details behind Saucony SILO, its elevated footwear collection blending the brand's rich heritage and technology with high-fashion influences. Challenging the expectations of traditional luxury sneakers, the collection incorporates premium materials and a fresh, refined approach to some of Saucony's most iconic designs. With an emphas ...

公司产品候选项目情况 - 公司有四个产品候选项目，SPC - 15用于治疗PTSD和焦虑症，SP - 26用于治疗纤维肌痛和慢性疼痛，SPC - 14用于治疗阿尔茨海默病，SPU - 16用于治疗中枢神经系统疾病，初始针对多发性硬化症[237][240][244][246] 产品候选项目研发计划 - 公司预计2025年提交SPC - 15的IND申请，目前正在进行GLP合规的药代动力学和药效学研究[238] - 2025年初开始对SP - 26进行初始动物研究，评估其剂量、缓释和吸收情况[240] 产品候选项目市场机会 - 全球阿尔茨海默病治疗市场预计到2033年将超过308亿美元，SPC - 14有发展机会[244] - 纤维肌痛影响约400万美国成年人，占人口的2%，SP - 26可作为非阿片类替代方案[243] 公司股票回购计划 - 2023 - 2024年公司股票回购计划授权回购最多200万美元股票，共回购355,710股，总成本644,234美元，2024年全部取消[248] 公司营收情况 - 2024年和2023年公司营收均为72,102美元，与Aikido许可和分许可协议有关[250][251] 公司营收成本情况 - 2024年和2023年公司营收成本均为5,838美元，为UMB许可和分许可协议的许可费[250][252] 公司运营费用及研发费用情况 - 2024年公司运营费用为4,771,958美元，2023年为3,921,856美元，其中2024年研发费用为2,368,156美元，2023年为845,092美元[250][253] - 2024年和2023年研发费用分别为2368156美元和845092美元，增长1523064美元，增幅180.2%[256] 公司销售、一般和行政费用情况 - 2024年和2023年销售、一般和行政费用分别为298284美元和479078美元，减少180794美元，降幅37.7%[258] 公司持续经营业务亏损情况 - 2024年和2023年持续经营业务亏损分别为4705694美元和3855592美元，增加850102美元，增幅22.1%[259] 公司其他收入净额情况 - 2024年和2023年其他收入净额分别为312814美元和224509美元，增加88305美元，增幅39.3%[260] 公司终止经营业务亏损情况 - 2024年和2023年终止经营业务亏损分别为0美元和69600美元，减少69600美元[262] 公司净亏损情况 - 2024年公司净亏损4,392,880美元，2023年为3,700,683美元[250] - 2024年和2023年净亏损分别为4392880美元和3700683美元，增加692197美元，增幅18.7%[263] 公司营运资金情况 - 2024年和2023年营运资金分别为5455483美元和6905568美元，减少1450085美元，降幅21%[265] 公司经营活动净现金情况 - 2024年和2023年经营活动使用的净现金分别为3833914美元和3224498美元，增加609416美元，增幅18.9%[267] 公司投资活动净现金情况 - 2024年和2023年投资活动提供（使用）的净现金分别为973777美元和 - 4147107美元，正向变化5120884美元，增幅123.5%[269] 公司融资活动净现金情况 - 2024年和2023年融资活动提供（使用）的净现金分别为3241628美元和 - 471121美元，正向变化3712749美元，增幅788%[270]

文章核心观点 公司宣布其主要资产SPC - 15开展IND - 使能的GLP合规毒理学和毒代动力学研究首次给药，若相关研究成功将提供开启IND所需的最后临床前数据 [1][2] 分组1：SPC - 15研究进展 - 公司宣布其主要资产SPC - 15开展IND - 使能的GLP合规毒理学和毒代动力学研究首次给药 [1] - 若IND - 使能安全研究及同期GLP合规药代动力学和药效学研究成功，将提供开启SPC - 15 IND所需的最后临床前数据 [2] - 公司于2024年9月完成预IND会议，与FDA就SPC - 15的505(b)(2)监管途径达成一致 [2] 分组2：SPC - 15介绍 - SPC - 15是一种鼻内血清素5 - HT4受体激动剂，用于治疗应激性精神障碍如PTSD和焦虑 [3] - SPC - 15有资格走FDA简化的505(b)(2)监管途径，有望加速审批流程 [3] - 公司与哥伦比亚大学合作开展SPC - 15临床前研究，并拥有其全球独家开发和商业化权利 [3] 分组3：公司介绍 - 公司是一家处于发展阶段的生物制药公司，专注于解决未满足医疗需求的疾病 [4] - 公司产品组合包括针对PTSD的SPC - 15、针对纤维肌痛和慢性疼痛的SP - 26等 [4] - 公司研究与顶尖大学和实验室合作开展 [4]